

































**FIG. 4.** Diagnostic and management toolboxes with specific tools to facilitate diagnosis and management of malnutrition, frailty, and sarcopenia in patients with cirrhosis.

skeletal myopathy may be partially reversible with alcohol cessation.<sup>(188)</sup> Although the exact mechanisms linking NAFLD with sarcopenia and sarcopenic obesity are not well understood, the shared

pathophysiologic processes of chronic inflammation and insulin resistance (that lead to both NAFLD and sarcopenia) suggest that interventions targeting NAFLD have the potential to prevent muscle loss.























certification by the Food and Drug Administration of clinically meaningful endpoints of frailty and sarcopenia.

*Acknowledgment:* The authors are grateful for the valuable contributions of the AASLD Practice Guideline Committee (PGC), particularly Barry Schlansky. Members of the PGC include George Ioannou (chair), Rabab Ali, Scott W. Biggins, Roniel Cabrera, Henry Chang, Michael F. Chang, David S. Goldberg, Ruben Hernaez, Binu John, Patricia D. Jones, W. Ray Kim (board liaison), Cynthia Levy, Jeff McIntyre, Jessica L. Mellinger, Mindie H. Nguyen, Nadia Ovchinsky, Mary E.M. Rinella (board liaison), Anjana A. Pillai, Daniel S. Pratt, Hugo R. Rosen, Barry Schlansky, Matthew J. Stotts, Christopher J. Sonnenday, Lisa B. VanWagner, and Elizabeth C. Verna.

## REFERENCES

- Lochs H, Allison SP, Meier R, Pirlich M, Kondrup J, Schneider ST, et al. Introductory to the ESPEN Guidelines on Enteral Nutrition: terminology, definitions and general topics. *Clin Nutr* 2006;25:180-186. <https://doi.org/10.1016/j.clnu.2006.02.007>.
- Morley JE, Vellas B, Abellan van Kan G, Anker SD, Bauer JM, Bernabei R, et al. Frailty consensus: a call to action. *J Am Med Dir Assoc* 2013;14:392-397.
- Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 2019;48:16-31. <https://doi.org/10.1093/ageing/afy169>.
- World Health Organization. Malnutrition. [https://www.who.int/health-topics/malnutrition#tab=tab\\_1](https://www.who.int/health-topics/malnutrition#tab=tab_1). Accessed June 15, 2020.
- Bunchorntavakul C, Reddy KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis. *Aliment Pharmacol Ther* 2020;51:64-77. <https://doi.org/10.1111/apt.15571>.
- Eslamparast T, Montano-Loza AJ, Raman M, Tandon P. Sarcopenic obesity in cirrhosis—the confluence of 2 prognostic titans. *Liver Int* 2018;38:1706-1717. <https://doi.org/10.1111/liv.13876>.
- Volk ML, Fisher N, Fontana RJ. Patient knowledge about disease self-management in cirrhosis. *Am J Gastroenterol* 2013;108:302-305. <https://doi.org/10.1038/ajg.2012.214>.
- Beg S, Curtis S, Shariff M. Patient education and its effect on self-management in cirrhosis: a pilot study. *Eur J Gastroenterol Hepatol* 2016;28:582-587. <https://doi.org/10.1097/MEG.0000000000000579>.
- Morando F, Rosi S, Gola E, Nardi M, Piano S, Fasolato S, et al. Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study. *Liver Int* 2015;35:1508-1515. <https://doi.org/10.1111/liv.12583>.
- Wu J, Meng QH. Current understanding of the metabolism of micronutrients in chronic alcoholic liver disease. *World J Gastroenterol* 2020;26:4567-4578. <https://doi.org/10.3748/wjg.v26.i31.4567>.
- Sanvisens A, Zuluaga P, Pineda M, Fuster D, Bolao F, Juncà J, et al. Folate deficiency in patients seeking treatment of alcohol use disorder. *Drug Alcohol Depend* 2017;180:417-422. <https://doi.org/10.1016/j.drugalcdep.2017.08.039>.
- Lewis MJ. Alcoholism and nutrition: a review of vitamin supplementation and treatment. *Curr Opin Clin Nutr Metab Care* 2020;23:138-144. <https://doi.org/10.1097/MCO.0000000000000622>.
- Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. *Am J Gastroenterol* 2001;96:2745-2750.
- Jorgensen RA, Lindor KD, Sartin JS, LaRusso NF, Wiesner RH. Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis. *J Clin Gastroenterol* 1995;20:215-219. <https://doi.org/10.1097/00004836-199504000-00011>.
- Holick MF. Vitamin D deficiency. *N Engl J Med* 2007;357:266-281. <https://doi.org/10.1056/NEJMr070553>.
- Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. *Dig Dis Sci* 2009;55:2624-2628. <https://doi.org/10.1007/s10620-009-1069-9>.
- Kubesch A, Quenstedt L, Saleh M, Rüschenbaum S, Schwarzkopf K, Martinez Y, et al. Vitamin D deficiency is associated with hepatic decompensation and inflammation in patients with liver cirrhosis: a prospective cohort study. *PLoS One* 2018;13:e0207162. <https://doi.org/10.1371/journal.pone.0207162>.
- Guo G-Y, Shi Y-Q, Wang L, Ren X, Han Z-Y, Guo C-C, et al. Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis. *Aliment Pharmacol Ther* 2015;42:221-230. <https://doi.org/10.1111/apt.13244>.
- Riggio O, Merli M, Capocaccia L, Caschera M, Zullo A, Pinto G, et al. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. *HEPATOLOGY* 1992;16:785-789. <https://doi.org/10.1002/hep.1840160326>.
- Nishikawa H, Yoh K, Enomoto H, Iwata Y, Sakai Y, Kishino K, et al. Serum zinc level is associated with frailty in chronic liver diseases. *J Clin Med* 2020;9:1570. <https://doi.org/10.3390/jcm9051570>.
- Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, et al. Serum zinc concentration and sarcopenia: a close linkage in chronic liver diseases. *J Clin Med* 2019;8:336. <https://doi.org/10.3390/jcm8030336>.
- Rocchi E, Borella P, Borghi A, Paolillo F, Pradelli M, Farina F, et al. Zinc and magnesium in liver cirrhosis. *Eur J Clin Invest* 1994;24:149-155. <https://doi.org/10.1111/j.1365-2362.1994.tb00980.x>.
- Aagaard NK, Andersen H, Vilstrup H, Clausen T, Jakobsen J, Dørup I. Muscle strength, Na, K-pumps, magnesium and potassium in patients with alcoholic liver cirrhosis—relation to spironolactone. *J Intern Med* 2002;252:56-63. <https://doi.org/10.1046/j.1365-2796.2002.01008.x>.
- Aagaard NK, Andersen H, Vilstrup H, Clausen T, Jakobsen J, Dørup I. Decreased muscle strength and contents of Mg and Na, K-pumps in chronic alcoholics occur independently of liver cirrhosis. *J Intern Med* 2003;253:359-366. <https://doi.org/10.1046/j.1365-2796.2003.01100.x>.
- Heubi JE, Higgins JV, Argao EA, Sierra RI, Specker BL. The role of magnesium in the pathogenesis of bone disease in childhood cholestatic liver disease: a preliminary report. *J Pediatr Gastroenterol Nutr* 1997;25:301-306. <https://doi.org/10.1097/00005176-199709000-00010>.
- Maillette de Buy Wenniger L, Beuers U. Bile salts and cholestasis. *Dig Liver Dis* 2010;42:409-418. <https://doi.org/10.1016/j.dld.2010.03.015>.
- Yu R, Wang Y, Xiao Y, Mo L, Liu A, Li D, et al. Prevalence of malnutrition and risk of undernutrition in hospitalised children

- with liver disease. *J Nutr Sci* 2017;6:e55. <https://doi.org/10.1017/jns.2017.56>.
- 28) Venu M, Martin E, Saeian K, Gawrieh S. High prevalence of vitamin A deficiency and vitamin D deficiency in patients evaluated for liver transplantation. *Liver Transpl* 2013;19:627-633. <https://doi.org/10.1002/lt.23646>.
  - 29) Owen OE, Reichle FA, Mozzoli MA, Kreulen T, Patel MS, Elfenbein IB, et al. Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis. *J Clin Invest* 1981;68:240-252. <https://doi.org/10.1172/JCI110240>.
  - 30) Owen OE, Trapp VE, Reichard GA, Mozzoli MA, Moctezuma J, Paul P, et al. Nature and quantity of fuels consumed in patients with alcoholic cirrhosis. *J Clin Invest* 1983;72:1821-1832. <https://doi.org/10.1172/JCI111142>.
  - 31) Madden AM, Morgan MY. Resting energy expenditure should be measured in patients with cirrhosis, not predicted. *HEPATOLOGY* 1999;30:655-664. <https://doi.org/10.1002/hep.510300326>.
  - 32) Peng S, Plank LD, McCall JL, Gillanders LK, McLroy K, Gane EJ. Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study. *Am J Clin Nutr* 2007;85:1257-1266.
  - 33) Eslamparast T, Vandermeer B, Raman M, Gramlich L, Den Heyer V, Belland D, et al. Are predictive energy expenditure equations accurate in cirrhosis? *Nutrients* 2019;11:334. <https://doi.org/10.3390/nu11020334>.
  - 34) Mullen KD, Denne SC, McCullough AJ, Savin SM, Bruno D, Tavill AS, et al. Leucine metabolism in stable cirrhosis. *HEPATOLOGY* 1986;6:622-630. <https://doi.org/10.1002/hep.1840060412>.
  - 35) Yamato M, Muto Y, Yoshida T, Kato M, Moriwaki H. Clearance rate of plasma branched-chain amino acids correlates significantly with blood ammonia level in patients with liver cirrhosis. *Int Hepatol Commun* 1995;3:91-96. [https://doi.org/10.1016/0928-4346\(94\)00159-3](https://doi.org/10.1016/0928-4346(94)00159-3).
  - 36) Montanari A, Simoni I, Vallisa D, Trifirò A, Colla R, Abbiati R, et al. Free amino acids in plasma and skeletal muscle of patients with liver cirrhosis. *HEPATOLOGY* 1988;8:1034-1039. <https://doi.org/10.1002/hep.1840080509>.
  - 37) Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. *HEPATOLOGY* 2014;60:715-735.
  - 38) Shawcross DL, Wright GAK, Stadlbauer V, Hodges SJ, Davies NA, Wheeler-Jones C, et al. Ammonia impairs neutrophil phagocytic function in liver disease. *HEPATOLOGY* 2008;48:1202-1212. <https://doi.org/10.1002/hep.22474>.
  - 39) Shalimar, Sheikh MF, Mookerjee RP, Agarwal B, Acharya SK, Jalan R. Prognostic role of ammonia in patients with cirrhosis. *HEPATOLOGY* 2019;70:982-994. <https://doi.org/10.1002/hep.30534>.
  - 40) Chen HW, Dunn MA. Muscle at risk: the multiple impacts of ammonia on sarcopenia and frailty in cirrhosis. *Clin Transl Gastroenterol* 2016;7:e170. <https://doi.org/10.1038/ctg.2016.33>.
  - 41) Dasarathy S, Hatzoglou M. Hyperammonemia and proteostasis in cirrhosis. *Curr Opin Clin Nutr Metab Care* 2018;21:30-36. <https://doi.org/10.1097/MCO.0000000000000426>.
  - 42) Davuluri G, Allawy A, Thapaliya S, Rennison JH, Singh D, Kumar A, et al. Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress. *J Physiol* 2016;594:7341-7360. <https://doi.org/10.1113/JP272796>.
  - 43) Welch N, Dasarathy J, Runkana A, Penumatsa R, Bellar A, Reen J, et al. Continued muscle loss increases mortality in cirrhosis: impact of aetiology of liver disease. *Liver Int* 2020;40:1178-1188. <https://doi.org/10.1111/liv.14358>.
  - 44) Vural A, Attaway A, Welch N, Zein J, Dasarathy S. Skeletal muscle loss phenotype in cirrhosis: a nationwide analysis of hospitalized patients. *Clin Nutr* 2020;39:3711-3720. <https://doi.org/10.1016/j.clnu.2020.03.032>.
  - 45) DiMartini A, Cruz RJ, Dew MA, Myaskovsky L, Goodpaster B, Fox K, et al. Muscle mass predicts outcomes following liver transplantation. *Liver Transpl* 2013;19:1172-1180. <https://doi.org/10.1002/lt.23724>.
  - 46) Thapaliya S, Runkana A, McMullen MR, Nagy LE, McDonald C, Prasad SVN, et al. Alcohol-induced autophagy contributes to loss in skeletal muscle mass. *Autophagy* 2014;10:677-690. <https://doi.org/10.4161/auto.27918>.
  - 47) Bousquet-Dubouch M-P, Nguen S, Bouyssié D, Burlet-Schiltz O, French SW, Monsarrat B, et al. Chronic ethanol feeding affects proteasome-interacting proteins. *Proteomics* 2009;9:3609-3622. <https://doi.org/10.1002/pmic.200800959>.
  - 48) Lang CH, Frost RA, Svanberg E, Vary TC. IGF-I/IGFBP-3 ameliorates alterations in protein synthesis, eIF4E availability, and myostatin in alcohol-fed rats. *Am J Physiol Endocrinol Metab* 2004;286:E916-E926. <https://doi.org/10.1152/ajpen.00554.2003>.
  - 49) Bhanji RA, Narayanan P, Allen AM, Malhi H, Watt KD. Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. *HEPATOLOGY* 2017;66:2055-2065. <https://doi.org/10.1002/hep.29420>.
  - 50) Abrigo J, Gonzalez F, Aguirre F, Tacchi F, Gonzalez A, Meza MP, et al. Cholic acid and deoxycholic acid induce skeletal muscle atrophy through a mechanism dependent on TGR5 receptor. *J Cell Physiol* 2021;236:260-272. <https://doi.org/10.1002/jcp.29839>.
  - 51) Tapper EB, Aberasturi D, Zhao Z, Hsu CY, Parikh ND. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. *Aliment Pharmacol Ther* 2020;51:1397-1405. <https://doi.org/10.1111/apt.15749>.
  - 52) Aqel BA, Scolapio JS, Dickson RC, Burton DD, Bouras EP. Contribution of ascites to impaired gastric function and nutritional intake in patients with cirrhosis and ascites. *Clin Gastroenterol Hepatol* 2005;3:1095-1100. [https://doi.org/10.1016/S1542-3565\(05\)00531-8](https://doi.org/10.1016/S1542-3565(05)00531-8).
  - 53) Dolz C, Raurich JM, Ibáñez J, Obrador A, Marsé P, Gayá J. Ascites increases the resting energy expenditure in liver cirrhosis. *Gastroenterology* 1991;100:738-744. [https://doi.org/10.1016/0016-5085\(91\)80019-6](https://doi.org/10.1016/0016-5085(91)80019-6).
  - 54) Lai JC, Rahimi RS, Verna EC, Kappas MR, Dunn MA, McAdams-DeMarco M, et al. Frailty associated with waitlist mortality independent of ascites and hepatic encephalopathy in a multicenter study. *Gastroenterology* 2019;156:1675-1682. <https://doi.org/10.1053/j.gastro.2019.01.028>.
  - 55) Ebadi M, Bhanji RA, Mazurak VC, Montano-Loza AJ. Sarcopenia in cirrhosis: from pathogenesis to interventions. *J Gastroenterol* 2019;54:845-859. <https://doi.org/10.1007/s00535-019-01605-6>.
  - 56) Santetti D, de Albuquerque Wilasco MI, Dornelles CTL, Werlang ICR, Fontella FU, Kieling CO, et al. Serum proinflammatory cytokines and nutritional status in pediatric chronic liver disease. *World J Gastroenterol* 2015;21:8927-8934. <https://doi.org/10.3748/wjg.v21.i29.8927>.
  - 57) Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. *J Hepatol* 2016;65:1232-1244. <https://doi.org/10.1016/j.jhep.2016.07.040>.
  - 58) Arroyo V, García-Martínez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. *J Hepatol* 2014;61:396-407. <https://doi.org/10.1016/j.jhep.2014.04.012>.
  - 59) Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. *J Hepatol* 2014;61:1385-1396. <https://doi.org/10.1016/j.jhep.2014.08.010>.

- 60) Dalle S, Rossmeislova L, Koppo K. The role of inflammation in age-related sarcopenia. *Front Physiol* 2017;8:1045. <https://doi.org/10.3389/fphys.2017.01045>.
- 61) Soysal P, Stubbs B, Lucato P, Luchini C, Solmi M, Peluso R, et al. Inflammation and frailty in the elderly: a systematic review and meta-analysis. *Ageing Res Rev* 2016;31:1-8. <https://doi.org/10.1016/j.arr.2016.08.006>.
- 62) Nishitsuji H, Funami K, Shimizu Y, Ujino S, Sugiyama K, Seya T, et al. Hepatitis C virus infection induces inflammatory cytokines and chemokines mediated by the cross talk between hepatocytes and stellate cells. *J Virol* 2013;87:8169-8178. <https://doi.org/10.1128/JVI.00974-13>.
- 63) Saraiva GN, Rosário NFd, Medeiros T, Leite PEC, Lacerda GdS, Andrade TGd, et al. Restoring inflammatory mediator balance after sofosbuvir-induced viral clearance in patients with chronic hepatitis C. *Mediators Inflamm* 2018;2018:8578051. <https://doi.org/10.1155/2018/8578051>
- 64) Gao B, Tsukamoto H. Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe? *Gastroenterology* 2016;150:1704-1709. <https://doi.org/10.1053/j.gastro.2016.01.025>.
- 65) Dasarathy S. The pathogenesis of physical frailty and sarcopenia. In: Tandon P, Montano-Loza AJ, eds. *Frailty and Sarcopenia in Cirrhosis*. Cham, Switzerland: Springer International Publishing; 2020:33-53. [https://doi.org/10.1007/978-3-030-26226-6\\_4](https://doi.org/10.1007/978-3-030-26226-6_4).
- 66) Moctezuma-Velázquez C, Low G, Mourtzakis M, Ma M, Burak KW, Tandon P, et al. Association between low testosterone levels and sarcopenia in cirrhosis: a cross-sectional study. *Ann Hepatol* 2018;17:615-623. <https://doi.org/10.5604/01.3001.0012.0930>.
- 67) Sinclair M, Grossmann M, Hoermann R, Angus PW, Gow PJ. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial. *J Hepatol* 2016;65:906-913. <https://doi.org/10.1016/j.jhep.2016.06.007>.
- 68) Haugen CE, McAdams-DeMarco M, Verna EC, Rahimi RS, Kappus MR, Dunn MA, et al. Association between liver transplant wait-list mortality and frailty based on body mass index. *JAMA Surg* 2019;154:1103-1109. <https://doi.org/10.1001/jamasurg.2019.2845>.
- 69) Kashiwagi K, Takayama M, Fukuhara K, Shimizu-Hirota R, Chu P-S, Nakamoto N, et al. A significant association of non-obese non-alcoholic fatty liver disease with sarcopenic obesity. *Clin Nutr ESPEN* 2020;38:86-93. <https://doi.org/10.1016/j.clnesp.2020.05.025>.
- 70) Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CMM, Sawyer MB, Beaumont C, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. *J Cachexia Sarcopenia Muscle* 2015;7:126-135. <https://doi.org/10.1002/jcsm.12039>.
- 71) Nishikawa H, Nishiguchi S. Sarcopenia and sarcopenic obesity are prognostic factors for overall survival in patients with cirrhosis. *Intern Med* 2016;55:855-856. <https://doi.org/10.2169/intermalmedicine.55.6298>.
- 72) Orman ES, Roberts A, Ghabril M, Nephew L, Desai AP, Patidar K, et al. Trends in characteristics, mortality, and other outcomes of patients with newly diagnosed cirrhosis. *JAMA Netw Open* 2019;2:e196412. <https://doi.org/10.1001/jamanetworkopen.2019.6412>.
- 73) Welch N, Attaway A, Bellar A, Alkhafaji H, Vural A, Dasarathy S. Compound sarcopenia in hospitalized patients with cirrhosis worsens outcomes with increasing age. *Nutrients* 2021;13:659. <https://doi.org/10.3390/nu13020659>.
- 74) Hayashi F, Matsumoto Y, Momoki C, Yuikawa M, Okada G, Hamakawa E, et al. Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. *Hepatol Res* 2013;43:1264-1275. <https://doi.org/10.1111/hepr.12085>.
- 75) Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. *Am J Transplant* 2014;14:1870-1879. <https://doi.org/10.1111/ajt.12762>.
- 76) Dunn MA, Josbeno DA, Schmotzer AR, Tevar AD, DiMartini AF, Landsittel DP, et al. The gap between clinically assessed physical performance and objective physical activity in liver transplant candidates. *Liver Transpl* 2016;22:1-22. <https://doi.org/10.1002/lt.24506>.
- 77) Chascsa DM, Lai JC, Dunn MA, Montano-Loza AJ, Kappus MR, Dasarathy S, et al. Patient and caregiver attitudes and practices of exercise in candidates listed for liver transplantation. *Dig Dis Sci* 2018;63:3290-3296. <https://doi.org/10.1007/s10620-018-5271-5>.
- 78) Román E, Torrades MT, Nadal MJ, Cárdenas G, Nieto JC, Vidal S, et al. Randomized pilot study: effects of an exercise programme and leucine supplementation in patients with cirrhosis. *Dig Dis Sci* 2014;59:1966-1975. <https://doi.org/10.1007/s10620-014-3086-6>.
- 79) Román E, García-Galcerán C, Torrades T, Herrera S, Marín A, Doñate M, et al. Effects of an exercise programme on functional capacity, body composition and risk of falls in patients with cirrhosis: a randomized clinical trial. *PLoS One* 2016;11:e0151652. <https://doi.org/10.1371/journal.pone.0151652>.
- 80) Zenith L, Meena N, Ramadi A, Yavari M, Harvey A, Carbonneau M, et al. Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2014;12:1920-1926. <https://doi.org/10.1016/j.cgh.2014.04.016>.
- 81) Kruger C, McNeely ML, Bailey RJ, Yavari M, Abraldes JG, Carbonneau M, et al. Home exercise training improves exercise capacity in cirrhosis patients: role of exercise adherence. *Sci Rep* 2018;8:99. <https://doi.org/10.1038/s41598-017-18320-y>.
- 82) Hiraoka A, Michitaka K, Kiguchi D, Izumoto H, Ueki H, Kaneto M, et al. Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis. *Eur J Gastroenterol Hepatol* 2017;29:1416-1423. <https://doi.org/10.1097/MEG.0000000000000986>.
- 83) Centers for Disease Control and Prevention. Social determinants of health: Know what affects health. <https://www.cdc.gov/socialdeterminants/index.htm>. Accessed August 16, 2020.
- 84) Bittermann T, Dwinnells K, Chadha S, Wolf MS, Olthoff KM, Serper M. Low health literacy is associated with frailty and reduced likelihood of liver transplant listing: a prospective cohort study. *Liver Transpl* 2020;26:1409-1421. <https://doi.org/10.1002/lt.25830>.
- 85) Golovaty I, Tien PC, Price JC, Sheira L, Seligman H, Weiser SD. Food insecurity may be an independent risk factor associated with nonalcoholic fatty liver disease among low-income adults in the United States. *J Nutr* 2020;150:91-98. <https://doi.org/10.1093/jn/nxz212>.
- 86) Bajaj JS, Wade JB, Gibson DP, Heuman DM, Thacker LR, Sterling RK, et al. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. *Am J Gastroenterol* 2011;106:1646-1653. <https://doi.org/10.1038/ajg.2011.157>.
- 87) Wadhvani SI, Beck AF, Bucuvalas J, Gottlieb L, Kotagal U, Lai JC. Neighborhood socioeconomic deprivation is associated with worse patient and graft survival following pediatric liver transplantation. *Am J Transplant* 2020;20:1597-1605. <https://doi.org/10.1111/ajt.15786>.
- 88) Thuluvath PJ, Thuluvath AJ, Savva Y. Karnofsky performance status before and after liver transplantation predicts graft and patient survival. *J Hepatol* 2018;69:818-825. <https://doi.org/10.1016/j.jhep.2018.05.025>.

- 89) Tandon P, Reddy KR, O'Leary JG, Garcia-Tsao G, Abraldes JG, Wong F, et al. A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis. *HEPATOLOGY* 2017;65:217-224. <https://doi.org/10.1002/hep.28900>.
- 90) Lai JC, Covinsky KE, Dodge JL, Boscardin WJ, Segev DL, Roberts JP, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. *HEPATOLOGY* 2017;66:564-574. <https://doi.org/10.1002/hep.29219>.
- 91) Kardashian A, Ge J, McCulloch CE, Kappus MR, Dunn MA, Duarte-Rojo A, et al. Identifying an optimal liver frailty index cutoff to predict waitlist mortality in liver transplant candidates. *HEPATOLOGY* 2020;73:1132-1139. <https://doi.org/10.1002/hep.31406>.
- 92) Lai JC, Dodge JL, Kappus MR, Dunn MA, Volk ML, Duarte-Rojo A, et al. Changes in frailty are associated with waitlist mortality in patients with cirrhosis. *J Hepatol* 2020;73:575-581. <https://doi.org/10.1016/j.jhep.2020.03.029>.
- 93) Lurz E, Quammie C, Englesbe M, Alonso EM, Lin HC, Hsu EK, et al. Frailty in children with liver disease: a prospective multicenter study. *J Pediatr* 2018;194:109-115.e4. <https://doi.org/10.1016/j.jpeds.2017.10.066>.
- 94) Perito ER, Bucuvalas J, Lai JC. Functional status at listing predicts waitlist and posttransplant mortality in pediatric liver transplant candidates. *Am J Transplant* 2018;19:1-21. <https://doi.org/10.1111/ajt.15203>.
- 95) Tapper EB, Konerman M, Murphy S, Sonnenday CJ. Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index. *Am J Transplant* 2018;18:2566-2570. <https://doi.org/10.1111/ajt.15020>.
- 96) Tandon P, Tangri N, Thomas L, Zenith L, Shaikh T, Carbonneau M, et al. A rapid bedside screen to predict unplanned hospitalization and death in outpatients with cirrhosis: a prospective evaluation of the Clinical Frailty Scale. *Am J Gastroenterol* 2016;111:1759-1767. <https://doi.org/10.1038/ajg.2016.303>.
- 97) Tapper EB, Finkelstein D, Mittelman MA, Piatkowski G, Lai M. Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis. *HEPATOLOGY* 2015;62:584-590. <https://doi.org/10.1002/hep.27830>.
- 98) Tapper EB, Baki J, Parikh ND, Lok AS. Frailty, psychoactive medications, and cognitive dysfunction are associated with poor patient-reported outcomes in cirrhosis. *HEPATOLOGY* 2019;69:1676-1685. <https://doi.org/10.1002/hep.30336>.
- 99) Lai JC, Segev DL, McCulloch CE, Covinsky KE, Dodge JL, Feng S. Physical frailty after liver transplantation. *Am J Transplant* 2018;18:1986-1994. <https://doi.org/10.1111/ajt.14675>.
- 100) Samoylova ML, Covinsky KE, Haftek M, Kuo S, Roberts JP, Lai JC. Disability in patients with end-stage liver disease: results from the functional assessment in liver transplantation study. *Liver Transpl* 2017;23:292-298. <https://doi.org/10.1002/lt.24684>.
- 101) Thuluvath PJ, Thuluvath AJ, Savva Y, Zhang T. Karnofsky performance status following liver transplantation in patients with multiple organ failures and probable acute-on-chronic liver failure. *Clin Gastroenterol Hepatol* 2020;18:234-241. <https://doi.org/10.1016/j.cgh.2019.03.016>.
- 102) Bernal W, Martin-Mateos R, Lipcsey M, Tallis C, Woodsford K, McPhail MJ, et al. Aerobic capacity during cardiopulmonary exercise testing and survival with and without liver transplantation for patients with chronic liver disease. *Liver Transpl* 2013;20:54-62. <https://doi.org/10.1002/lt.23766>.
- 103) Wallace D, Cowling TE, Walker K, Suddle A, Gimson A, Rowe I, et al. The impact of performance status on length of hospital stay and clinical complications following liver transplantation. *Transplantation* 2020 Oct 8. <https://doi.org/10.1097/TP.0000000000003484>. [Epub ahead of print]
- 104) Wallace D, Cowling T, McPhail MJ, Brown SE, Aluvihare V, Suddle A, et al. Assessing the time-dependent impact of performance status on outcomes after liver transplantation. *HEPATOLOGY* 2020;72:1341-1352. <https://doi.org/10.1002/hep.31124>.
- 105) Dunn MA, Josbeno DA, Tevar AD, Rachakonda V, Ganesh SR, Schmotzer AR, et al. Frailty as tested by gait speed is an independent risk factor for cirrhosis complications that require hospitalization. *Am J Gastroenterol* 2016;111:1768-1775. <https://doi.org/10.1038/ajg.2016.336>.
- 106) Sinclair M, Poltavskiy E, Dodge JL, Lai JC. Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist. *World J Gastroenterol* 2017;23:899-905. <https://doi.org/10.3748/wjg.v23.i5.899>.
- 107) Carey EJ, Steidley DE, Aqel BA, Byrne TJ, Mekeel KL, Rakela J, et al. Six-minute walk distance predicts mortality in liver transplant candidates. *Liver Transpl* 2010;16:1373-1378. <https://doi.org/10.1002/lt.22167>.
- 108) Prentis JM, Manas DMD, Trenell MI, Hudson M, Jones DJ, Snowden CP. Submaximal cardiopulmonary exercise testing predicts 90-day survival after liver transplantation. *Liver Transpl* 2012;18:152-159. <https://doi.org/10.1002/lt.22426>.
- 109) Tapper EB, Zhao L, Nikirk S, Baki J, Parikh ND, Lok AS, et al. Incidence and bedside predictors of the first episode of overt hepatic encephalopathy in patients with cirrhosis. *Am J Gastroenterol* 2020;115:2017-2025. <https://doi.org/10.14309/ajg.0000000000000762>.
- 110) Tapper EB, Derstine B, Baki J, Su GL. Bedside measures of frailty and cognitive function correlate with sarcopenia in patients with cirrhosis. *Dig Dis Sci* 2019;64:3652-3659. <https://doi.org/10.1007/s10620-019-05713-4>.
- 111) Cron DC, Friedman JF, Winder GS, Thelen AE, Derck JE, Fakhoury JW, et al. Depression and frailty in patients with end-stage liver disease referred for transplant evaluation. *Am J Transplant* 2016;16:1805-1811. <https://doi.org/10.1111/ajt.13639>.
- 112) Derck JE, Thelen AE, Cron DC, Friedman JF, Gerebics AD, Englesbe MJ, et al. Quality of life in liver transplant candidates. *Transplantation* 2015;99:340-344. <https://doi.org/10.1097/TP.0000000000000593>.
- 113) Lai JC, Dodge JL, McCulloch CE, Covinsky KE, Singer JP. Frailty and the burden of concurrent and incident disability in patients with cirrhosis: a prospective cohort study. *Hepatol Commun* 2020;4:126-133. <https://doi.org/10.1002/hep4.1444>.
- 114) Tapper EB, Nikirk S, Parikh N, Zhao L. Falls are common, morbid, and predictable in patients with cirrhosis. *J Hepatol* 2021 Apr 19. <https://doi.org/10.1016/j.jhep.2021.04.012>. [Epub ahead of print]
- 115) Kremer WM, Nagel M, Reuter M, Hilscher M, Michel M, Kaps L, et al. Validation of the Clinical Frailty Scale for the prediction of mortality in patients with liver cirrhosis. *Clin Transl Gastroenterol* 2020;11:e00211. <https://doi.org/10.14309/ctg.0000000000000211>.
- 116) Orman ES, Ghabril M, Chalasani N. Poor performance status is associated with increased mortality in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2016;14:1189-1195.e1. <https://doi.org/10.1016/j.cgh.2016.03.036>.
- 117) Dolgin NH, Martins PNA, Movahedi B, Lapane KL, Anderson FA, Bozorgzadeh A. Functional status predicts postoperative mortality after liver transplantation. *Clin Transplant* 2016;30:1403-1410. <https://doi.org/10.1111/ctr.12808>.
- 118) Hsu C-Y, Lee Y-H, Hsia C-Y, Huang Y-H, Su C-W, Lin H-C, et al. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. *HEPATOLOGY* 2013;57:112-119. <https://doi.org/10.1002/hep.25950>.

- 119) Jacob M, Copley LP, Lewsey JD, Gimson A, Rela M, van der Meulen JHP. Functional status of patients before liver transplantation as a predictor of posttransplant mortality. *Transplantation* 2005;80:52-57. <https://doi.org/10.1097/01.TP.0000163292.03640.5C>.
- 120) Jo HB, Lee JK, Kang HW, Kim JH, Lim YJ, Koh M-S, et al. Safety and effectiveness of midazolam for cirrhotic patients undergoing endoscopic variceal ligation. *Turk J Gastroenterol* 2018;29:448-455. <https://doi.org/10.5152/tjg.2018.17589>.
- 121) Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. *HEPATOLOGY* 2014;60:192-201. <https://doi.org/10.1002/hep.27057>.
- 122) Álvares-da-Silva MR, Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. *Nutrition* 2005;21:113-117. <https://doi.org/10.1016/j.nut.2004.02.002>.
- 123) Wang CW, Feng S, Covinsky KE, Hayssen H, Zhou L-Q, Yeh BM, et al. A comparison of muscle function, mass, and quality in liver transplant candidates. *Transplantation* 2016;100:1692-1698. <https://doi.org/10.1097/TP.0000000000001232>.
- 124) Haugen CE, McAdams-DeMarco MA, Verna EC, et al. Association between liver transplant wait-list mortality and frailty based on body mass index. *JAMA Surg*. 2019;154 1103-1109.
- 125) Haugen CE, McAdams-DeMarco M, Holscher CM, Ying H, Gurakar AO, Garonzik-Wang J, et al. Multicenter study of age, frailty, and waitlist mortality among liver transplant candidates. *Ann Surg* 2020;271:1132-1136. <https://doi.org/10.1097/SLA.0000000000003207>.
- 126) Lai JC, Ganger DR, Volk ML, Dodge JL, Dunn MA, Duarte-Rojo A, et al. Association of frailty and sex with wait list mortality in liver transplant candidates in the Multicenter Functional Assessment in Liver Transplantation (FrAILT) Study. *JAMA Surg* 2021;156:256-262. <https://doi.org/10.1001/jamasurg.2020.5674>.
- 127) Skladany L, Drotarova Z, Vnencakova J, Jancekova D, Molcan P, Koller T. Applicability and prognostic value of frailty assessment tools among hospitalized patients with advanced chronic liver disease. *Croat Med J* 2021;62:8-16. <https://doi.org/10.3325/cmj.2021.62.8>.
- 128) Ney M, Haykowsky MJ, Vandermeer B, Shah A, Ow M, Tandon P. Systematic review: pre- and post-operative prognostic value of cardiopulmonary exercise testing in liver transplant candidates. *Aliment Pharmacol Ther* 2016;44:796-806. <https://doi.org/10.1111/apt.13771>.
- 129) Carey EJ, Lai JC, Sonnenday C, Tapper EB, Tandon P, Duarte-Rojo A, et al. A North American expert opinion statement on sarcopenia in liver transplantation. *HEPATOLOGY* 2019;70:1816-1829. <https://doi.org/10.1002/hep.30828>.
- 130) Paris MT, Tandon P, Heyland DK, Furberg H, Premji T, Low G, et al. Automated body composition analysis of clinically acquired computed tomography scans using neural networks. *Clin Nutr* 2020;39:3049-3055. <https://doi.org/10.1016/j.clnu.2020.01.008>.
- 131) Carey EJ, Lai JC, Wang CW, Dasarathy S, Lobach I, Montano-Loza AJ, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. *Liver Transpl* 2017;23:625-633. <https://doi.org/10.1002/lt.24750>.
- 132) Wells CI, McCall JL, Plank LD. Relationship between total body protein and cross-sectional skeletal muscle area in liver cirrhosis is influenced by overhydration. *Liver Transpl* 2019;25:45-55. <https://doi.org/10.1002/lt.25314>.
- 133) Ebadi M, Wang CW, Lai JC, Dasarathy S, Kappus MR, Dunn MA, et al. Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis. *J Cachexia Sarcopenia Muscle* 2018;9:1053-1062. <https://doi.org/10.1002/jcsm.12349>.
- 134) Praktiknjo M, Book M, Luetkens J, Pohlmann A, Meyer C, Thomas D, et al. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis. *HEPATOLOGY* 2018;67:1014-1026. <https://doi.org/10.1002/hep.29602>.
- 135) Pirlich M, Schutz T, Spachos T, Ertl S, Weis M, Lochs H, et al. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. *HEPATOLOGY* 2000;32:1208-1215. <https://doi.org/10.1053/jhep.2000.20524>.
- 136) Ruiz-Margáin A, Xie JJ, Román-Calleja BM, Pauly M, White MG, Chapa-Ibargüengoitia M, et al. Phase angle from bioelectrical impedance for the assessment of sarcopenia in cirrhosis with or without ascites. *Clin Gastroenterol Hepatol* 2020 Sep 2. <https://doi.org/10.1016/j.cgh.2020.08.066>. [Epub ahead of print]
- 137) Fernando Gomes Romeiro L, Augusti S. Nutritional assessment in cirrhotic patients with hepatic encephalopathy. *World J Hepatol* 2015;7:2940-2954. <https://doi.org/10.4254/wjh.v7.i30.2940>.
- 138) Hara N, Iwasa M, Iwata K, Miyachi H, Tanaka H, Takeo M, et al. Value of the extracellular water ratio for assessment of cirrhotic patients with and without ascites. *Hepatol Res* 2009;39:1072-1079. <https://doi.org/10.1111/j.1872-034X.2009.00546.x>.
- 139) Hara N, Iwasa M, Sugimoto R, Mifuji-Moroka R, Yoshikawa K, Terasaka E, et al. Sarcopenia and sarcopenic obesity are prognostic factors for overall survival in patients with cirrhosis. *Intern Med* 2016;55:863-870. <https://doi.org/10.2169/internalmedicine.55.5676>.
- 140) Viertel M, Bock C, Reich M, Löser S, Plauth M. Performance of CT-based low skeletal muscle index, low mean muscle attenuation, and bioelectric impedance derived low phase angle in the detection of an increased risk of nutrition related mortality. *Clin Nutr* 2019;38:2375-2380. <https://doi.org/10.1016/j.clnu.2018.10.018>.
- 141) Bellafronte NT, Diani LM, Vega-Piris L, Cuadrado GB, Chiarello PG. Comparison between dual-energy X-ray absorptiometry and bioelectrical impedance for body composition measurements in adults with chronic kidney disease: a cross-sectional, longitudinal, multi-treatment analysis. *Nutrition* 2021;82:111059. <https://doi.org/10.1016/j.nut.2020.111059>.
- 142) Giusto M, Lattanzi B, Albanese C, Galtieri A, Farcomeni A, Giannelli V, et al. Sarcopenia in liver cirrhosis: the role of computed tomography scan for the assessment of muscle mass compared with dual-energy X-ray absorptiometry and anthropometry. *Eur J Gastroenterol Hepatol* 2015;27:328-334. <https://doi.org/10.1097/MEG.0000000000000274>.
- 143) Labio ED, Del Rosario DB, Strasser SI, McCaughan GW, Crawford BA. Effect of ascites on bone density measurement in cirrhosis. *J Clin Densitom* 2007;10:391-394. <https://doi.org/10.1016/j.jocd.2007.07.001>.
- 144) Lindqvist C, Brismar TB, Majeed A, Wählén S. Assessment of muscle mass depletion in chronic liver disease: dual-energy X-ray absorptiometry compared with computed tomography. *Nutrition* 2019;61:93-98. <https://doi.org/10.1016/j.nut.2018.10.031>.
- 145) Sinclair M, Hoermann R, Peterson A, Testro A, Angus PW, Hey P, et al. Use of dual X-ray absorptiometry in men with advanced cirrhosis to predict sarcopenia-associated mortality risk. *Liver Int* 2019;39:1089-1097. <https://doi.org/10.1111/liv.14071>.
- 146) WHO Multicentre Growth Reference Study Group. Reliability of anthropometric measurements in the WHO Multicentre Growth Reference Study. *Acta Paediatr Suppl* 2007;450:38-46. <https://doi.org/10.1111/j.1651-2227.2006.tb02374.x>.
- 147) Mangus RS, Bush WJ, Miller C, Kubal CA. Severe sarcopenia and increased fat stores in pediatric patients with liver, kidney, or intestine failure. *J Pediatr Gastroenterol Nutr* 2017;65:579-583. <https://doi.org/10.1097/MPG.0000000000001651>.

- 148) Squires RH, Ng V, Romero R, Ekong U, Hardikar W, Emre S, et al. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. *HEPATOLOGY* 2014;60:362-398. <https://doi.org/10.1002/hep.27191>.
- 149) Young S, Kwarta E, Azzam R, Sentongo T. Nutrition assessment and support in children with end-stage liver disease. *Nutr Clin Pract* 2013;28:317-329. <https://doi.org/10.1177/0884533612474043>.
- 150) Grutters LA, Pennings JP, Bruggink JLM, Viddeleer AR, Verkade HJ, de Kleine RHJ, et al. Body composition of infants with biliary atresia: anthropometric measurements and computed tomography-based body metrics. *J Pediatr Gastroenterol Nutr* 2020;71:440-445. <https://doi.org/10.1097/MPG.00000000000002859>.
- 151) Ooi PH, Thompson-Hodgetts S, Pritchard-Wiart L, Gilmour SM, Mager DR. Pediatric sarcopenia: a paradigm in the overall definition of malnutrition in children? *JPEN* 2020;44:407-418. <https://doi.org/10.1002/jpen.1681>.
- 152) Lurz E, Patel H, Lebovic G, Quammie C, Woolfson JP, Perez M, et al. Paediatric reference values for total psoas muscle area. *J Cachexia Sarcopenia Muscle* 2020;11:405-414. <https://doi.org/10.1002/jcsm.12514>.
- 153) Mazurak VC, Tandon P, Montano-Loza AJ. Nutrition and the transplant candidate. *Liver Transpl* 2017;23:1451-1464. <https://doi.org/10.1002/lt.24848>.
- 154) Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. *Liver Transpl* 2012;18:1209-1216. <https://doi.org/10.1002/lt.23495>.
- 155) Ooi PH, Mazurak VC, Bhargava R, Dunichand-Hoedl A, Romero RA, Gilmour SM, et al. Myopenia and reduced subcutaneous adiposity in children with liver disease are associated with adverse outcomes. *JPEN* 2020 July 25. <https://doi.org/10.1002/jpen.1963>. [Epub ahead of print]
- 156) Woolfson JP, Perez M, Chavhan GB, Johara FT, Lurz E, Kamath BM, et al. Sarcopenia in children with end-stage liver disease on the transplant waiting list. *Liver Transpl* 2021;27:641-651. <https://doi.org/10.1002/lt.25985>.
- 157) Montano-Loza AJ, Meza-Junco J, Prado CMM, Lieffers JR, Baracos VE, Bain VG, et al. Muscle wasting is associated with mortality in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2012;10:166-173.e1. <https://doi.org/10.1016/j.cgh.2011.08.028>.
- 158) Belarmino G, Gonzalez MC, Sala P, Torrinhas RS, Andraus W, D'Albuquerque LAC, et al. Diagnosing sarcopenia in male patients with cirrhosis by dual-energy X-ray absorptiometry estimates of appendicular skeletal muscle mass. *JPEN* 2018;42:24-36. <https://doi.org/10.1177/0148607117701400>.
- 159) van Vugt JLA, Levolver S, de Bruin RWF, van Rosmalen J, Metselaar HJ, IJzermans JNM. Systematic review and meta-analysis of the impact of computed tomography-assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation. *Am J Transplant* 2016;16:2277-2292. <https://doi.org/10.1111/ajt.13832>.
- 160) Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, et al. Sarcopenia and mortality after liver transplantation. *J Am Coll Surg* 2010;211:271-278. <https://doi.org/10.1016/j.jamcollsurg.2010.03.039>.
- 161) Kaido T, Ogawa K, Fujimoto Y, Ogura Y, Hata K, Ito T, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. *Am J Transplant* 2013;13:1549-1556. <https://doi.org/10.1111/ajt.12221>.
- 162) Hamaguchi Y, Kaido T, Okumura S, Fujimoto Y, Ogawa K, Mori A, et al. Impact of quality as well as quantity of skeletal muscle on outcomes after liver transplantation. *Liver Transpl* 2014;20:1413-1419. <https://doi.org/10.1002/lt.23970>.
- 163) Kuo SZ, Ahmad M, Dunn MA, Montano-Loza AJ, Carey EJ, Lin S, et al. Sarcopenia predicts posttransplant mortality in acutely ill men undergoing urgent evaluation and liver transplantation. *Transplantation* 2019;103:2312-2317. <https://doi.org/10.1097/TP.0000000000002741>.
- 164) Marasco G, Serenari M, Renzulli M, Alemanni LV, Rossini B, Pettinari I, et al. Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments. *J Gastroenterol* 2020;55:927-943. <https://doi.org/10.1007/s00535-020-01711-w>.
- 165) Hari A, Berzigotti A, Štabuc B, Caglević N. Muscle psoas indices measured by ultrasound in cirrhosis—preliminary evaluation of sarcopenia assessment and prediction of liver decompensation and mortality. *Dig Liver Dis* 2019;51:1502-1507. <https://doi.org/10.1016/j.dld.2019.08.017>.
- 166) Tapper EB, Zhang P, Garg R, Nault T, Leary K, Krishnamurthy V, et al. Body composition predicts mortality and decompensation in compensated cirrhosis patients: a prospective cohort study. *JHEP Rep* 2020;2:100061. <https://doi.org/10.1016/j.jhepr.2019.11.005>.
- 167) Ando Y, Ishigami M, Ito T, Ishizu Y, Kuzuya T, Honda T, et al. Sarcopenia impairs health-related quality of life in cirrhotic patients. *Eur J Gastroenterol Hepatol* 2019;31:1550-1556. <https://doi.org/10.1097/MEG.0000000000001472>.
- 168) Montano-Loza AJ, Meza-Junco J, Baracos VE, Prado CMM, Ma M, Meeberg G, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. *Liver Transpl* 2014;20:640-648. <https://doi.org/10.1002/lt.23863>.
- 169) Georgiou A, Papatheodoridis GV, Alexopoulou A, Deutsch M, Vlachogiannakos I, Ioannidou P, et al. Validation of cutoffs for skeletal muscle mass index based on computed tomography analysis against dual energy X-ray absorptiometry in patients with cirrhosis: the KIRRHOS study. *Ann Gastroenterol* 2020;33:80-86. <https://doi.org/10.20524/aog.2019.0432>.
- 170) Carias S, Castellanos AL, Vilchez V, Nair R, Dela Cruz AC, Watkins J, et al. Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation. *J Gastroenterol Hepatol* 2016;31:628-633. <https://doi.org/10.1111/jgh.13166>.
- 171) Kalafateli M, Mantzoukis K, Choi Yau Y, Mohammad AO, Arora S, Rodrigues S, et al. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-Stage Liver Disease score. *J Cachexia Sarcopenia Muscle* 2016;8:113-121. <https://doi.org/10.1002/jcsm.12095>.
- 172) Kobayashi K, Maruyama H, Kiyono S, Ogasawara S, Suzuki E, Ooka Y, et al. Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis. *J Gastroenterol* 2018;53:652-659. <https://doi.org/10.1007/s00535-017-1378-2>.
- 173) Tandon M, Singh H, Singla N, Jain P, Pandey CK. Tongue thickness in health vs cirrhosis of the liver: prospective observational study. *World J Gastrointest Pharmacol Ther* 2020;11:59-68. <https://doi.org/10.4292/wjgpt.v11.i3.59>.
- 174) Tandon P, Mourtzakis M, Low G, Zenith L, Ney M, Carbonneau M, et al. Comparing the variability between measurements for sarcopenia using magnetic resonance imaging and computed tomography imaging. *Am J Transplant* 2016;16:2766-2767. <https://doi.org/10.1111/ajt.13832>.
- 175) Strauss BJ, Gibson PR, Stroud DB, Borovnicar DJ, Xiong DW, Keogh J. Total body dual X-ray absorptiometry is a good measure

- of both fat mass and fat-free mass in liver cirrhosis compared to “gold-standard” techniques. *Ann N Y Acad Sci* 2000;904:55-62.
- 176) Wang NC, Zhang P, Tapper EB, Saini S, Wang SC, Su GL. Automated measurements of muscle mass using deep learning can predict clinical outcomes in patients with liver disease. *Am J Gastroenterol* 2020;115:1210-1216. <https://doi.org/10.14309/ajg.0000000000000662>.
  - 177) Kim G, Kang SH, Kim MY, Baik SK. Prognostic value of sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis. *PLoS One* 2017;12:e0186990. <https://doi.org/10.1371/journal.pone.0186990>.
  - 178) Lurz E, Patel H, Frimpong RG, Ricciuto A, Kehar M, Wales PW, et al. Sarcopenia in children with end-stage liver disease. *J Pediatr Gastroenterol Nutr* 2018;66:222-226. <https://doi.org/10.1097/MPG.0000000000001792>.
  - 179) Foster C, Baki J, Nikirk S, Williams S, Parikh ND, Tapper EB. Comprehensive health-state utilities in contemporary patients with cirrhosis. *Hepatology* 2020;4:852-858. <https://doi.org/10.1002/hep4.1512>.
  - 180) Derck JE, Thelen AE, Cron DC, Friedman JF, Gerebics AD, Englesbe MJ, et al. Quality of life in liver transplant candidates: frailty is a better indicator than severity of liver disease. *Transplantation* 2015;99:340-344. <https://doi.org/10.1097/TP.0000000000000593>.
  - 181) Plank LD, Gane EJ, Peng S, Muthu C, Mathur S, Gillanders L, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. *HEPATOLOGY* 2008;48:557-566. <https://doi.org/10.1002/hep.22367>.
  - 182) Ruiz JG, Dent E, Morley JE, Merchant RA, Beilby J, Beard J, et al. Screening for and managing the person with frailty in primary care: ICFSR Consensus Guidelines. *J Nutr Health Aging* 2020;24:920-927. <https://doi.org/10.1007/s12603-020-1492-3>.
  - 183) Boushousa RSSB, Lourenço RP, Côrtes DM, Oliveira LPM, Lyra AC, de Jesus RP. Comparison between criteria for diagnosing malnutrition in patients with advanced chronic liver disease: GLIM group proposal versus different nutritional screening tools. *J Hum Nutr Diet* 2020;33:862-868. <https://doi.org/10.1111/jhn.12759>.
  - 184) Traub J, Bergheim I, Horvath A, Stadlbauer V. Validation of malnutrition screening tools in liver cirrhosis. *Nutrients* 2020;12:1306. <https://doi.org/10.3390/nu12051306>.
  - 185) Wu Y, Zhu Y, Feng Y, Wang R, Yao N, Zhang M, et al. Royal Free Hospital-Nutritional Prioritizing Tool improves the prediction of malnutrition risk outcomes in liver cirrhosis patients compared with Nutritional Risk Screening 2002. *Br J Nutr* 2020;124:1293-1302. <https://doi.org/10.1017/S0007114520002366>.
  - 186) Georgiou A, Papatheodoridis GV, Alexopoulou A, Deutsch M, Vlachogiannakos I, Ioannidou P, et al. Evaluation of the effectiveness of eight screening tools in detecting risk of malnutrition in cirrhotic patients: the KIRRHOS study. *Br J Nutr* 2019;122:1368-1376. <https://doi.org/10.1017/S0007114519002277>.
  - 187) Borhofen SM, Gerner C, Lehmann J, Fimmers R, Görtzen J, Hey B, et al. The Royal Free Hospital-Nutritional Prioritizing Tool is an independent predictor of deterioration of liver function and survival in cirrhosis. *Dig Dis Sci* 2015;61:1735-1743. <https://doi.org/10.1007/s10620-015-4015-z>.
  - 188) Peters TJ, Martin F, Ward K. Chronic alcoholic skeletal myopathy—common and reversible. *Alcohol* 1985;2:485-489. [https://doi.org/10.1016/0741-8329\(85\)90120-X](https://doi.org/10.1016/0741-8329(85)90120-X).
  - 189) Kumar A, Davuluri G, Silva RNE, Engelen MPKJ, Ten Have GAM, Prayson R, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. *HEPATOLOGY* 2017;65:2045-2058. <https://doi.org/10.1002/hep.29107>.
  - 190) Hiramatsu A, Aikata H, Uchikawa S, Ohya K, Kodama K, Nishida Y, et al. Levocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosis. *Hepatology* 2019;3:348-355. <https://doi.org/10.1002/hep4.1309>.
  - 191) Ohara M, Ogawa K, Suda G, Kimura M, Machara O, Shimazaki T, et al. L-Carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis. *Hepatology* 2018;2:910-922. <https://doi.org/10.1002/hep4.1207>.
  - 192) Malaguarnera M, Vacante M, Giordano M, Pennisi G, Bella R, Rampello L, et al. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. *Am J Clin Nutr* 2011;93:799-808. <https://doi.org/10.3945/ajcn.110.007393>.
  - 193) Martí-Carvajal AJ, Gluud C, Arevalo-Rodriguez I, Martí-Amarista CE. Acetyl-L-carnitine for patients with hepatic encephalopathy. *Cochrane Database Syst Rev* 2019;2019:CD011451. <https://doi.org/10.1002/14651858.CD011451.pub2>.
  - 194) Makhlof NA, Mahran ZG, Sadek SH, Magdy DM, Makhlof HA. Six-minute walk test before and after large-volume paracentesis in cirrhotic patients with refractory ascites: a pilot study. *Arab J Gastroenterol* 2019;20:81-85. <https://doi.org/10.1016/j.ajg.2019.05.009>.
  - 195) Hanai T, Shiraki M, Miwa T, Watanabe S, Imai K, Suetsugu A, et al. Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis: loop diuretics and muscle in cirrhosis. *Hepatology* 2019;49:82-95. <https://doi.org/10.1111/hepr.13244>.
  - 196) Allard JP, Chau J, Sandokji K, Blendis LM, Wong F. Effects of ascites resolution after successful TIPSS on nutrition in cirrhotic patients with refractory ascites. *Am J Gastroenterol* 2001;96:2442-2447. <https://doi.org/10.1111/j.1572-0241.2001.04051.x>.
  - 197) Tsien C, Shah SN, McCullough AJ, Dasarathy S. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic shunt. *Eur J Gastroenterol Hepatol* 2013;25:85-93.
  - 198) Artru F, Miquet X, Azahaf M, Labreuche J, Ntandja Wandji LC, Sergeant G, et al. Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: a large retrospective CT-based surveillance. *Aliment Pharmacol Ther* 2020;52:1516-1526. <https://doi.org/10.1111/apt.16080>.
  - 199) Benmassaoud A, Roccarina D, Arico F, Leandro G, Yu B, Cheng F, et al. Sarcopenia does not worsen survival in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt for refractory ascites. *Am J Gastroenterol* 2020;115:1911-1914. <https://doi.org/10.14309/ajg.0000000000000959>.
  - 200) Kaido T, Tamai Y, Hamaguchi Y, Okumura S, Kobayashi A, Shirai H, et al. Effects of pretransplant sarcopenia and sequential changes in sarcopenic parameters after living donor liver transplantation. *Nutrition* 2017;33:195-198. <https://doi.org/10.1016/j.nut.2016.07.002>.
  - 201) Tsien C, Garber A, Narayanan A, Shah SN, Barnes D, Egtesad B, et al. Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation. *J Gastroenterol Hepatol* 2014;29:1250-1257. <https://doi.org/10.1111/jgh.12524>.
  - 202) Dasarathy S. Posttransplant sarcopenia: an underrecognized early consequence of liver transplantation. *Dig Dis Sci* 2013;58:3103-3111. <https://doi.org/10.1007/s10620-013-2791-x>.
  - 203) Bergerson JT, Lee J-G, Furlan A, Sourianarayanan A, Fetzer DT, Tevar AD, et al. Liver transplantation arrests and reverses muscle wasting. *Clin Transplant* 2015;29:216-221. <https://doi.org/10.1111/ctr.12506>.
  - 204) Bhanji RA, Takahashi N, Moynagh MR, Narayanan P, Angirekula M, Mara KC, et al. The evolution and impact of sarcopenia pre- and post-liver transplantation. *Aliment Pharmacol Ther* 2019;49:807-813. <https://doi.org/10.1111/apt.15161>.
  - 205) Glass C, Hipskind P, Tsien C, Malin SK, Kasumov T, Shah SN, et al. Sarcopenia and a physiologically low respiratory quotient in patients with cirrhosis: a prospective controlled study. *J Appl*

- Physiol 2013;114:559-565. <https://doi.org/10.1152/jappphysiol.01042.2012>.
- 206) Glass C, Hipskind P, Cole D, Lopez R, Dasarathy S. Handheld calorimeter is a valid instrument to quantify resting energy expenditure in hospitalized cirrhotic patients: a prospective study. *Nutr Clin Pract* 2012;27:677-688. <https://doi.org/10.1177/0884533612446195>.
- 207) Greco AV, Mingrone G, Benedetti G, Capristo E, Tataranni PA, Gasbarrini G. Daily energy and substrate metabolism in patients with cirrhosis. *HEPATOLOGY* 1998;27:346-350. <https://doi.org/10.1002/hep.510270205>.
- 208) Guglielmi F, Panella C, Buda A, Budillon G, Caregaro L, Clerici C, et al. Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism: multicentre prospective study by the 'Nutritional Problems in Gastroenterology' Section of the Italian Society of Gastroenterology (SIGE). *Dig Liver Dis* 2005;37:681-688. <https://doi.org/10.1016/j.dld.2005.03.010>.
- 209) Riggio O, Angeloni S, Ciuffa L, Nicolini G, Attili AF, Albanese C, et al. Malnutrition is not related to alterations in energy balance in patients with stable liver cirrhosis. *Clin Nutr* 2003;22:553-559. [https://doi.org/10.1016/s0261-5614\(03\)00058-x](https://doi.org/10.1016/s0261-5614(03)00058-x).
- 210) Nielsen K, Kondrup J, Martinsen L, Døssing H, Larsson B, Stilling B, et al. Long-term oral refeeding of patients with cirrhosis of the liver. *Br J Nutr* 1995;74:557-567. <https://doi.org/10.1079/BJN19950158>.
- 211) European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. *J Hepatol* 2019;70:172-193. <https://doi.org/10.1016/j.jhep.2018.06.024>.
- 212) Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, et al. ESPEN guideline on clinical nutrition in liver disease. *Clin Nutr* 2019;38:485-521. <https://doi.org/10.1016/j.clnu.2018.12.022>.
- 213) Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. *HEPATOLOGY* 2013;58:325-336. <https://doi.org/10.1002/hep.26370>.
- 214) Swart GR, van den Berg JW, van Vuure JK, Rietveld T, Wattimena DL, Frenkel M. Minimum protein requirements in liver cirrhosis determined by nitrogen balance measurements at three levels of protein intake. *Clin Nutr* 1989;8:329-336. [https://doi.org/10.1016/0261-5614\(89\)90008-3](https://doi.org/10.1016/0261-5614(89)90008-3).
- 215) Swart GR, van den Berg JW, Wattimena JLD, Rietveld T, Van Vuure JK, Frenkel M. Elevated protein requirements in cirrhosis of the liver investigated by whole body protein turnover studies. *Clin Sci* 1988;75:101-107. <https://doi.org/10.1042/cs0750101>.
- 216) Nielsen K, Kondrup J, Martinsen L, Stilling B, Wikman B. Nutritional assessment and adequacy of dietary intake in hospitalized patients with alcoholic liver cirrhosis. *Br J Nutr* 1993;69:665-679. <https://doi.org/10.1079/BJN19930068>.
- 217) Córdoba J, López-Hellín J, Planas M, Sabin P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. *J Hepatol* 2004;41:38-43. <https://doi.org/10.1016/j.jhep.2004.03.023>.
- 218) Gheorghe L, Iacob R, Vădan R, Iacob S, Gheorghe C. Improvement of hepatic encephalopathy using a modified high-calorie high-protein diet. *Rom J Gastroenterol* 2005;14:231-238.
- 219) Charlton CP, Buchanan E, Holden CE, Preece MA, Green A, Booth IW, et al. Intensive enteral feeding in advanced cirrhosis: reversal of malnutrition without precipitation of hepatic encephalopathy. *Arch Dis Child* 1992;67:603-607. <https://doi.org/10.1136/adc.67.5.603>.
- 220) Uribe M, Marquez MA, Ramos GG, Ramos-Uribe MH, Vargas F, Villalobos A, et al. Treatment of chronic portal-systemic encephalopathy with vegetable and animal protein diets: a controlled crossover study. *Dig Dis Sci* 1982;27:1109-1116. <https://doi.org/10.1007/BF01391449>.
- 221) Bianchi GP, Marchesini G, Fabbri A, Rondelli A, Bugianesi E, Zoli M, et al. Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized crossover comparison. *J Intern Med* 1993;233:385-392. <https://doi.org/10.1111/j.1365-2796.1993.tb00689.x>.
- 222) Jonung T, Jeppsson B, Åslund U, Nair BM. A comparison between meat and vegan protein diet in patients with mild chronic hepatic encephalopathy. *Clin Nutr* 1987;6:169-174. [https://doi.org/10.1016/0261-5614\(87\)90052-5](https://doi.org/10.1016/0261-5614(87)90052-5).
- 223) Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. *Gastroenterology* 2003;124:1792-1801. [https://doi.org/10.1016/S0016-5085\(03\)00323-8](https://doi.org/10.1016/S0016-5085(03)00323-8).
- 224) Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. *J Hepatol* 1990;11:92-101. [https://doi.org/10.1016/0168-8278\(90\)90278-y](https://doi.org/10.1016/0168-8278(90)90278-y).
- 225) Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. *Clin Gastroenterol Hepatol* 2005;3:705-713. [https://doi.org/10.1016/s1542-3565\(05\)00017-0](https://doi.org/10.1016/s1542-3565(05)00017-0).
- 226) Plauth M, Egberts E-H, Hamster W, Török M, Müller PH, Brand O, et al. Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. *J Hepatol* 1993;17:308-314. [https://doi.org/10.1016/S0168-8278\(05\)80210-7](https://doi.org/10.1016/S0168-8278(05)80210-7).
- 227) Gluud LL, Dam G, Les I, Córdoba J, Marchesini G, Borre M, et al. Branched-chain amino acids for people with hepatic encephalopathy. *Cochrane Database Syst Rev* 2015:CD001939. <https://doi.org/10.1002/14651858.CD001939.pub2>.
- 228) Mager DR, Wykes LJ, Roberts EA, Ball RO, Pencharz PB. Branched-chain amino acid needs in children with mild-to-moderate chronic cholestatic liver disease. *J Nutr* 2006;136:133-139. <https://doi.org/10.1093/jn/136.1.133>.
- 229) Chin SE, Shepherd RW, Thomas BJ, Cleghorn GJ, Patrick MK, Wilcox JA, et al. Nutritional support in children with end-stage liver disease: a randomized crossover trial of a branched-chain amino acid supplement. *Am J Clin Nutr* 1992;56:158-163. <https://doi.org/10.1093/ajcn/56.1.158>.
- 230) Gielen E, Beckwée D, Delaere A, De Breucker S, Vandewoude M, Bautmans I, et al. Nutritional interventions to improve muscle mass, muscle strength, and physical performance in older people: an umbrella review of systematic reviews and meta-analyses. *Nutr Rev* 2021;79:121-147. <https://doi.org/10.1093/nutrit/nuaa011>.
- 231) Singh SS, Kumar A, Welch N, Sekar J, Mishra S, Bellar A, et al. Multiomics-identified intervention to restore ethanol-induced dysregulated proteostasis and secondary sarcopenia in alcoholic liver disease. *Cell Physiol Biochem* 2021;55:91-116. <https://doi.org/10.33594/000000327>.
- 232) Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. L-Ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. *Cochrane Database Syst Rev* 2018:CD012410. <https://doi.org/10.1002/14651858.CD012410.pub2>.
- 233) Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. *J Gastroenterol Hepatol* 2012;27:430-441. <https://doi.org/10.1111/j.1440-1746.2011.06951.x>.
- 234) Vaisman N, Katzman H, Carmiel-Haggai M, Lusthaus M, Niv E. Breakfast improves cognitive function in cirrhotic patients



- with cognitive impairment. *Am J Clin Nutr* 2010;92:137-140. <https://doi.org/10.3945/ajcn.2010.29211>.
- 235) Al-Obaid LN, Bazarbashi AN, Cohen ME, Kim J, Lei Y, Axelrad JE, et al. Enteric tube placement in patients with esophageal varices: risks and predictors of postinsertion gastrointestinal bleeding. *JGH Open* 2020;4:256-259. <https://doi.org/10.1002/jgh3.12255>.
- 236) Vidot H, Bowen DG, Carey S, McCaughan GW, Allman-Farinelli M, Shackel NA. Aggressive nutrition intervention reduces ascites and frequency of paracentesis in malnourished patients with cirrhosis and ascites: ascites and frequency of paracentesis. *JGH Open* 2017;1:92-97. <https://doi.org/10.1002/jgh3.12016>.
- 237) Baltz JG, Argo CK, Al-Osaimi AMS, Northup PG. Mortality after percutaneous endoscopic gastrostomy in patients with cirrhosis: a case series. *Gastrointest Endosc* 2010;72:1072-1075. <https://doi.org/10.1016/j.gie.2010.06.043>.
- 238) Berzigotti A, Albillos A, Villanueva C, Genescá J, Ardevol A, Agustín S, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. *HEPATOLOGY* 2017;65:1293-1305. <https://doi.org/10.1002/hep.28992>.
- 239) Villareal DT, Aguirre L, Gurney AB, Waters DL, Sinacore DR, Colombo E, et al. Aerobic or resistance exercise, or both, in dieting obese older adults. *N Engl J Med* 2017;376:1943-1955. <https://doi.org/10.1056/NEJMoa1616338>.
- 240) Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. *Cochrane Database Syst Rev* 2012:CD008344. <https://doi.org/10.1002/14651858.CD008344.pub2>.
- 241) Ney M, Vandermeer B, van Zanten SJV, Ma MM, Gramlich L, Tandon P. Meta-analysis: oral or enteral nutritional supplementation in cirrhosis. *Aliment Pharmacol Ther* 2013;37:672-679. <https://doi.org/10.1111/apt.12252>.
- 242) Moreno C, Deltenre P, Senterre C, Louvet A, Gustot T, Bastens B, et al. Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids. *Gastroenterology* 2016;150:903-910.e8. <https://doi.org/10.1053/j.gastro.2015.12.038>.
- 243) Reuter B, Shaw J, Hanson J, Tate V, Acharya C, Bajaj JS. Nutritional assessment in inpatients with cirrhosis can be improved after training and is associated with lower readmissions. *Liver Transpl* 2019;25:1790-1799. <https://doi.org/10.1002/lt.25602>.
- 244) McClave SA, Taylor BE, Martindale RG, Warren MM, Johnson DR, Braunschweig C, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). *J Parenter Enter Nutr* 2016;40:159-211. <https://doi.org/10.1177/0148607115621863>.
- 245) McClave SA, DiBaise JK, Mullin GE, Martindale RG. ACG clinical guideline: nutrition therapy in the adult hospitalized patient. *Am J Gastroenterol* 2016;111:315-334. <https://doi.org/10.1038/ajg.2016.28>.
- 246) Patel JJ, McClain CJ, Sarav M, Hamilton-Reeves J, Hurt RT. Protein requirements for critically ill patients with renal and liver failure. *Nutr Clin Pract* 2017;32(1 Suppl):101S-111S. <https://doi.org/10.1177/0884533616687501>.
- 247) Nanchal R, Subramanian R, Karvellas CJ, Hollenberg SM, Peppard WJ, Singbartl K, et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: cardiovascular, endocrine, hematologic, pulmonary, and renal considerations. *Crit Care Med* 2020;48:e173-e191. <https://doi.org/10.1097/CCM.0000000000004192>.
- 248) de Lédighen V, Beau P, Mannant PR, Borderie C, Ripault MP, Silvain C, et al. Early feeding or enteral nutrition in patients with cirrhosis after bleeding from esophageal varices? A randomized controlled study. *Dig Dis Sci* 1997;42:536-541. <https://doi.org/10.1023/a:1018838808396>.
- 249) Peter JV, Moran JL, Phillips-Hughes J. A metaanalysis of treatment outcomes of early enteral versus early parenteral nutrition in hospitalized patients. *Crit Care Med* 2005;33:213-220; discussion 260-261. <https://doi.org/10.1097/01.ccm.0000150960.36228.c0>.
- 250) Simpson F, Doig GS. Parenteral vs. enteral nutrition in the critically ill patient: a meta-analysis of trials using the intention to treat principle. *Intensive Care Med* 2005;31:12-23. <https://doi.org/10.1007/s00134-004-2511-2>.
- 251) Cheung K, Lee SS, Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. *Clin Gastroenterol Hepatol* 2012;10:117-125. <https://doi.org/10.1016/j.cgh.2011.08.016>.
- 252) Himoto T, Masaki T. Current trends of essential trace elements in patients with chronic liver diseases. *Nutrients* 2020;12:2084. <https://doi.org/10.3390/nu12072084>.
- 253) Kozeniecki M, Ludke R, Kerner J, Patterson B. Micronutrients in liver disease: roles, risk factors for deficiency, and recommendations for supplementation. *Nutr Clin Pract* 2020;35:50-62. <https://doi.org/10.1002/ncp.10451>.
- 254) Sriram K, Lonchyna VA. Micronutrient supplementation in adult nutrition therapy: practical considerations. *J Parenter Enter Nutr* 2009;33:548-562. <https://doi.org/10.1177/0148607108328470>.
- 255) Johnson TM, Overgard EB, Cohen AE, DiBaise JK. Nutrition assessment and management in advanced liver disease. *Nutr Clin Pract* 2013;28:15-29. <https://doi.org/10.1177/0884533612469027>.
- 256) Newsome PN, Beldon I, Moussa Y, Delahooke TE, Pouloupoulos G, Hayes PC, et al. Low serum retinol levels are associated with hepatocellular carcinoma in patients with chronic liver disease. *Aliment Pharmacol Ther* 2000;14:1295-1301. <https://doi.org/10.1046/j.1365-2036.2000.00849.x>.
- 257) Schölmerich J, Löhle E, Köttgen E, Gerok W. Zinc and vitamin A deficiency in liver cirrhosis. *Hepatogastroenterology* 1983;30:119-125.
- 258) Koop AH, Mousa OY, Pham LE, Corral-Hurtado JE, Pungpapong S, Keaveny AP. An argument for vitamin D, A, and zinc monitoring in cirrhosis. *Ann Hepatol* 2018;17:920-932. <https://doi.org/10.5604/01.3001.0012.7192>.
- 259) Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011;96:1911-1930. <https://doi.org/10.1210/jc.2011-0385>.
- 260) Heubi JE, Hollis BW, Specker B, Tsang RC. Bone disease in chronic childhood cholestasis: vitamin D absorption and metabolism. *HEPATOLOGY* 1989;9:258-264. <https://doi.org/10.1002/hep.1840090216>.
- 261) Altarelli M, Ben-Hamouda N, Schneider A, Berger MM. Copper deficiency: causes, manifestations, and treatment. *Nutr Clin Pract* 2019;34:504-513. <https://doi.org/10.1002/ncp.10328>.
- 262) Macías-Rodríguez RU, Ilarraz-Lomelí H, Ruiz-Margáin A, Ponce-de-León-Rosales S, Vargas-Voráčková F, García-Flores O, et al. Changes in hepatic venous pressure gradient induced by physical exercise in cirrhosis: results of a pilot randomized open clinical trial. *Clin Transl Gastroenterol* 2016;7:e180. <https://doi.org/10.1038/ctg.2016.38>.
- 263) Aamann L, Dam G, Borre M, Drljevic-Nielsen A, Overgaard K, Andersen H, et al. Resistance training increases muscle strength and muscle size in patients with liver cirrhosis. *Clin Gastroenterol Hepatol* 2020;18:1179-1187.e6. <https://doi.org/10.1016/j.cgh.2019.07.058>.

- 264) Chen HW, Ferrando A, White MG, Dennis RA, Xie J, Pauly M, et al. Home-based physical activity and diet intervention to improve physical function in advanced liver disease: a randomized pilot trial. *Dig Dis Sci* 2020;65:3350-3359. <https://doi.org/10.1007/s10620-019-06034-2>.
- 265) Lai JC, Dodge JL, Kappus MR, Wong R, Mohamad Y, Segev DL, et al. A multicenter pilot randomized clinical trial of a home-based exercise program for patients with cirrhosis: the Strength Training Intervention (STRIVE). *Am J Gastroenterol* 2021;116:717-722. <https://doi.org/10.14309/ajg.0000000000001113>.
- 266) Williams FR, Berzigotti A, Lord JM, Lai JC, Armstrong MJ. Review article: impact of exercise on physical frailty in patients with chronic liver disease. *Aliment Pharmacol Ther* 2019;50:988-1000. <https://doi.org/10.1111/apt.15491>.
- 267) Moore GE, Durstine JL, Painter PL, eds. *ACSM's Exercise Management for Persons with Chronic Diseases and Disabilities*. 4th ed. Champaign, IL: Human Kinetics; 2016.
- 268) US Department of Health & Human Services. Executive summary: physical activity guidelines for Americans. 2nd ed. [https://health.gov/sites/default/files/2019-10/PAG\\_ExecutiveSummary.pdf](https://health.gov/sites/default/files/2019-10/PAG_ExecutiveSummary.pdf). Published 2019. Accessed April 23, 2021.
- 269) Duarte-Rojo A, Bloomer PM, Rogers RJ, Hassan MA, Dunn MA, Tevar AD, et al. Introducing EL-FIT (Exercise and Liver FITness): a smartphone app to prehabilitate and monitor liver transplant candidates. *Liver Transpl* 2021;27:502-512. <https://doi.org/10.1002/lt.25950>.
- 270) Lai JC, Sonnenday CJ, Tapper EB, Duarte-Rojo A, Dunn MA, Bernal W, et al. Frailty in liver transplantation: an expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice. *Am J Transplant* 2019;19:1896-1906. <https://doi.org/10.1111/ajt.15392>.
- 271) Tandon P, Ismond KP, Riess K, Duarte-Rojo A, Al-Judaibi B, Dunn MA, et al. Exercise in cirrhosis: translating evidence and experience to practice. *J Hepatol* 2018;69:1164-1177. <https://doi.org/10.1016/j.jhep.2018.06.017>.
- 272) Lin FP, Ferrando AA, Dennis RA, Dunn MA, Kim WR, Duarte-Rojo A. Exercise-induced hyperammonemia does not precipitate overt hepatic encephalopathy. *HEPATOLOGY* 2020;72:778-780. <https://doi.org/10.1002/hep.31148>.
- 273) Bandi J-C, García-Pagán JC, Escorsell A, François E, Moitinho E, Rodés J, et al. Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis. *HEPATOLOGY* 1998;28:677-682. <https://doi.org/10.1002/hep.510280312>.
- 274) Bellar A, Welch N, Dasarathy S. Exercise and physical activity in cirrhosis: opportunities or perils. *J Appl Physiol* 2020;128:1547-1567. <https://doi.org/10.1152/jappphysiol.00798.2019>.
- 275) Kovacheva EL, Hikim APS, Shen R, Sinha I, Sinha-Hikim I. Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH<sub>2</sub>-terminal kinase, Notch, and Akt signaling pathways. *Endocrinology* 2010;151:628-638. <https://doi.org/10.1210/en.2009-1177>.

Author names in bold designate shared co-first authorship.